DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
about
SATB2 augments ΔNp63α in head and neck squamous cell carcinomaOncogenic Intra-p53 Family Member Interactions in Human CancersA microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase betap53 Family and Cellular Stress Responses in Cancer.Phosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradationATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damageExpression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings.Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancerThe p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancersGlobal tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance.Tumour suppressor genes in chemotherapeutic drug response.Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistanceArsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposurep63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.p63 and p73 in human cancer: defining the network.Therapeutic prospects for p73 and p63: rising from the shadow of p53.Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.HER2 expression predicts improved survival in patients with cervical node-positive head and neck squamous cell carcinoma.The role of p63 in cancer, stem cells and cancer stem cells.Tp63 in oral development, neoplasia, and autoimmunity.How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.Common Chromosomal Fragile Site Gene WWOX in Metabolic Disorders and TumorsAlterations of p63 and p73 in human cancers.Levels of the EMT-related protein Snail/Slug are not correlated with p53/p63 in cutaneous squamous cell carcinoma.ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapyPhospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells.Resveratrol-induced p53-independent apoptosis of human nasopharyngeal carcinoma cells is correlated with the downregulation of ΔNp63.Delineating Molecular Mechanisms of Squamous Tissue Homeostasis and Neoplasia: Focus on p63.Clinical relevance of the putative stem cell marker p63 in breast cancer.p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival.p63 and E-cadherin Expression in Canine Oral Squamous Cell Carcinoma.Genomic insights into head and neck cancer.
P2860
Q24299322-DB3C5214-B4A4-41C7-9D54-5B38E4726129Q26749382-26588F00-ED86-44D1-A93D-E99BFB2897A2Q30497990-8BB8C983-09E1-4B2B-A13F-48270BF22009Q33441772-CA300F3F-5004-4575-B8AC-88831E1BD01DQ33772427-B8C83F46-9523-405A-B2CB-A853180CE0DFQ34236112-F5CFFA36-2F12-4D57-937C-4D5657B08927Q34377287-11ED111C-0E97-453B-AA48-5CB1834999F3Q34438764-0F1F239D-1EF8-40B2-9710-05053F25ED62Q34753639-403DE825-4F3F-485D-ADFB-8A522EEB3248Q35070144-C9422DBF-52FF-465B-8E7D-7C12018CA4F9Q35220347-ABA1CBB1-EC92-4E69-827C-97BAB91DEF9CQ35227440-0B21FC32-70B5-4A26-AB09-DBFB029969A7Q35501271-A94E1CDD-A462-43FA-AB0E-5FAED864EAD6Q35745252-A11F9AC9-A36F-4AEB-BB86-185473DAA979Q36059712-CCADA753-0798-44C9-9254-C7DD313FE4FCQ36083098-7D329B8F-571C-47BA-9A5B-53E32CC125EDQ36392145-7AED1381-A6DE-4A99-88CA-DFAE5E3FE170Q36579412-1757A173-EFF3-4B02-98C6-798B834926E3Q36674365-A833D961-11E3-48ED-97C2-D280E918B703Q36694173-464C5926-356C-4B46-928E-851D184C8A5FQ36749787-C554AE01-267E-439F-B3F0-7565370BA42FQ36979908-60659796-36DC-498C-8CF9-46AA89649FC8Q37349935-BADC1833-41DE-4839-B41A-BE9710F99C7AQ37604597-0EA6CA58-27FF-42F1-A6FF-E4CF680CB070Q37858470-4F9F5DD5-2BAC-4478-B251-72F404C06BB7Q37885627-E51E42B5-ACCD-4290-87B2-FE3E941907DEQ38184518-C9A6CF52-B42D-420D-8F4D-B5BCD00141C2Q38187404-B0B7876C-05B8-4BE0-9EEC-806C254BAC76Q38247152-4A79B6E1-C202-4528-8A56-110D05877DE2Q38397621-03AE721F-4AD4-4ADE-80F7-37E3EB336AE8Q38798948-95AF7B23-1E63-4768-96BE-FD4B9A0B939CQ39120291-BEA5F09F-108A-4597-B234-03D9D4001958Q39201405-33A2FA6D-EB48-42C2-BD2F-0090DFF5D795Q39601518-B0971A19-9D5E-404B-BCB5-C321B07F5C70Q39665370-C3D58F1F-143D-42CD-9850-F95ECCAC7A6FQ40758235-C0CCD3B7-08DE-4914-80E1-FC18A37F6BF8Q42462630-28DB8299-4339-48A9-AEC7-BB3BE6278912Q46015653-1E7BA014-C2DA-49F8-BEE7-8CA20A4B0A1FQ48064789-2D28FA21-7530-4A9F-BECE-579A87C72A4EQ50917827-21147C1D-E3A7-4315-8B62-1F51A5040E76
P2860
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@en
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@nl
type
label
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@en
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@nl
prefLabel
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@en
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@nl
P2093
P356
P1433
P1476
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.
@en
P2093
David Sidransky
Edward Ratovitski
Rachel Zangen
P304
P356
10.4161/CC.4.10.2066
P577
2005-10-01T00:00:00Z